These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 22459549)

  • 1. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
    Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
    Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
    Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
    Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
    Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
    Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
    Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
    BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
    CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
    Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
    Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
    Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
    Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lasmiditan in patients with common migraine comorbidities: a
    Clemow DB; Baygani SK; Hauck PM; Hultman CB
    Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.
    Wilbraham D; Berg PH; Tsai M; Liffick E; Loo LS; Doty EG; Sellers E
    J Clin Pharmacol; 2020 Apr; 60(4):495-504. PubMed ID: 31745991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.
    Pearlman EM; Wilbraham D; Dennehy EB; Berg PH; Tsai M; Doty EG; Kay GG
    Hum Psychopharmacol; 2020 Sep; 35(5):e2732. PubMed ID: 32449213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
    Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
    J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
    Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
    Tepper SJ; Krege JH; Lombard L; Asafu-Adjei JK; Dowsett SA; Raskin J; Buchanan AS; Friedman DI
    Headache; 2019 Jul; 59(7):1052-1062. PubMed ID: 31152441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.